becomes increasingly likely. Full penetrance occurs at 39 and above.
Generally, the number of CAG repeats is inversely correlated with age of onset, but the correlation is far from perfect owing to modulating environmental and genetic factors. 5, 6 In some cases, the number of repeats is extremely high, resulting in juvenile-onset HD.
Repeat expansion occurs when mHTT is transmitted by the father, suggesting an effect on spermatogenesis. 4 CAG encodes the amino acid glutamine, and the expansion gives rise to proteins that have abnormally long poly-glutamine regions, which can form aggregates thought to interfere with many essential cellular proteins. 7 The result is cell dysfunction followed by cell death.
The brain region most severely affected by HD is the striatum, the main input structure of the basal ganglia. Autopsy reports of advanced HD patients indicate a loss of as many as 90% of striatal neurons. 8, 9 The substantial reduction in striatal size is accompanied by secondary enlargement of the lateral ventricles, perhaps the most striking morphological feature of HD. 10 Striatal pathology is strongly implicated in the motor deficits (chorea, dystonia, and late-stage bradykinesia), cognitive disorganization (disordered planning and impaired decision-making), and loss of emotional control (impulsiveness) in HD patients. 7 Closely associated with the striatum in both its anatomical and functional connections is the cerebral cortex. In fact, the striatum receives direct input from virtually all cortical regions, and like striatum, cortical atrophy is common in HD. The atrophy, however, is relatively heterogeneous, ranging widely in magnitude across cortical areas and across patient populations. 11 Frontal areas, including prefrontal cortex, are widely studied because they not only provide the bulk of cortical input to striatum, but also because of their close association with the striatum in processing motor, cognitive, and emotional information. 12, 13 Cortical atrophy occurs mainly in deep layers (III, V, and VI) and includes the loss of between at least 10 and more than 50% of both interneurons and pyramidal output neurons. In both cortex and striatum, neuronal loss is accompanied by substantial astrogliosis. 14, 15 Silencing the normal HTT gene in developing mouse cortex led to abnormal corticostriatal connectivity, including excessive excitatory synapse formation. 16 Thus, cortical HTT is required for the correct establishment of corticostriatal activity.
In fact, delivery of the mHTT gene to striatum and overlying cortex produced neuropathology and motor deficits in normal mice. 17 Huntington's disease (HD) neuropathology also has been identified in other brain regions, including hippocampus and thalamus, both of which have close ties to the corticostriatal system. It is even conceivable that abnormalities in the output of hippocampal and thalamic neurons underlie key aspects of corticostriatal neuropathology (eg, [18] [19] [20] . But the sheer magnitude of the neuropathology and its associated symptom profile suggest a primary role for the corticostriatal system in the onset and progression of HD symptoms.
Even more importantly for understanding the neural basis of HD, cortical and striatal neurons become dysfunctional long before they die, suggesting that insight into how these neurons operate and how they become dysfunctional holds the key for developing an effective treatment strategy.
The focus of this report is on corticostriatal abnormalities identified in transgenic mice that model HD. Not only do these models carry the HD genetic mutation and show HD behavioral signs to varying degrees of severity, but the mice also allow for the assessment of cellular and molecular processes not possible in human patients. Although numerous genetic models are used in HD research, they can be grouped into three categories-truncated, full-length, and knock-in-depending on the genetic context in which mHTT is expressed. The choice of model depends, at least in part, on the stage of the disease process under study as different models manifest neurological signs at different ages and at different levels of severity. Although no animal model provides a perfect recapitulation of HD, testing across multiple models provides a basis for identifying commonalities directly linked to the disease process. 21 Detailed reviews of transgenic animal models and their relation to the genetics, molecular pathology, and symptomatology of HD are available.
7,22-29 Table 1 provides a brief overview of the major categories of mouse models. Here, we review evidence of dysfunctional neuronal processing in both cortex and striatum of freely behaving mouse models tested at various stages of symptom severity. Because glutamate released by cortical projections is the primary driver of striatal neurons, we also review the potential contribution of a dysfunctional glutamate system in HD, including a change in the release of ascorbate, the reduced form of vitamin C known to modulate glutamate transmission (see 30,31).
| B EHAVIOR AL ELEC TROPHYS IOLOGY
Striatal projection neurons, also known as medium spiny neurons (MSNs) because of their cell body size and high number of dendritic spines, account for >90% of the neuronal population of the striatum. 32 Although MSNs modulate firing in relation to behavioral state, they tend to fire relatively slowly even during periods of behavioral activation (eg, 33-35) . When cortical input is absent, MSNs are silent and occupy a hyperpolarized or down state that suppresses spike activity. 36, 37 Convergent cortical input switches MSNs to a depolarized
Keypoints
• In behaving transgenic mice that model Huntington's disease, alterations in cortical and striatal electrophysiology appear to set the stage for the onset and progression of the behavioral phenotype.
• Suppression of the mutant huntingtin gene in cortical output neurons improves striatal processing and behavior.
• Increased expression of the major glutamate transport protein restores control of both glutamate and ascorbate homeostasis in striatum while normalizing striatal neuronal activity and improving some behavioral signs. CAG knock-in model, in which the mutation is "knocked into" the huntingtin gene and thus occurs in its proper genetic context, displays behavior-related firing rates comparable to those of WT controls. 45 Similar data have been reported for full-length models, such as the BACHD mouse, 46 which carries full-length mHTT expressed from a bacterial artificial chromosome transgene. 47 The critical variable appears not to be firing rate (number of spikes per unit time)
as much as the pattern of firing. In striatum, the firing pattern is altered in all HD models tested to date, including R6/2s, 48 and has even been reported for a transgenic rat model, 49 making it unlikely that a unique interaction between HD and the mouse genome can explain the abnormal electrophysiology. The change in firing pattern is manifest as a dramatic decrease in the occurrence of spike bursts.
Whereas 50% or more of WT spikes may be part of a bursting pattern, HD spikes tend to appear as single events even when the overall rate is elevated as in R6/2 mice. Bursting is believed to provide a mechanism for information transfer and plasticity in neural coding 50 suggesting that HD represents a loss of flexibility in striatal neural processing, a view consistent with behavioral evidence for a decline in motor and cognitive flexibility in HD mice.
28,51,52
Bursting deficits also occur in HD cortex. In medial prefrontal areas, which play an important role in cognition 53 and send a major glutamate projection to striatum, 54 R6/2, knock-in, and BACHD mice show significantly less bursting activity than their respective WT controls. 47 Firing rates also mimic what has been reported for striatum such that the R6/2 but not knock-in rate is significantly faster than WT. In an interesting parallel between R6/2 and human HD cortex, the faster R6/2 rate is consistent with increased cortical neuron excitability in both R6/2 mice 55 and HD patients. 56 A decrease in spike bursts also has been reported for primary motor cortex in a full-length transgenic mouse model. 46 Thus, the neuronal abnormalities identified in HD striatum also appear in multiple areas of cortex, implicating a large-scale corticostriatal communication problem.
That it occurs in models long before the onset of a clear behavioral phenotype reinforces the view that aberrant corticostriatal activity sets the stage for, rather than is secondary to, HD neurological signs.
Prelimbic cortex (PL), a subregion of the medial prefrontal area, plays a critical role in the expression of conditioned fear, a paradigm in which mice learn to freeze in response to a cue that predicts foot shock. 57 Because learning occurs rapidly, Walker Additional evidence of a processing deficit in HD is the decline in synchrony or correlated activity between simultaneously recorded neuron pairs. Correlated firing is a prominent feature of WT striatum and cortex but is markedly attenuated in HD models. In fact, all HD models tested to date-truncated, knock-in, and full-length-fail to match WT mice in the number of correlated neuronal pairs recorded in either striatum, prefrontal cortex, or motor cortex. 45, 46, 59 The decline in correlated firing within striatal or cortical sites in HD models suggests a failure in corticostriatal communication.
Direct support for this view comes from simultaneous recordings of local network activity in two closely interconnected areas:
primary motor cortex and dorsal striatum. Hong et al 51 Another interesting outcome of this investigation is that suppression of mHTT in cortical output neurons does not normalize cortical activity. In fact, multiple measures of burst firing were significantly elevated above WT in BE cortex, and simultaneously recorded neuron pairs in BE cortex showed less correlated firing than cortical neurons in WT mice. 46 Although mHTT is reduced in BE cortex, cortical neurons continue to receive input from interneurons and cortical afferents that still express mHTT. By itself, therefore, the suppression of mHTT in cortical outputs is not sufficient to rescue all the electrophysiological properties of these neurons.
But despite abnormalities in cortical firing, activity in BE striatum moves toward the WT pattern and away from BACHD, suggesting that genetic reduction in full-length mHTT alters how cortical neurons communicate with their striatal targets. Extreme changes in BE cortical activity may be required to reverse at least some aspects of BE striatal activity. Because burst firing is thought to strengthen neuronal processing, 50,65 the abnormal bursting observed in BE cortex may represent a compensatory response to dysfunctional cortical inputs that express mHTT.
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| G LUTA M ATE DYS R EG U L ATI O N
Although mHTT plays a key role in the corticostriatal communication problem in HD, the role of glutamate, the excitatory amino acid released by cortical afferents, is far from settled. As an excitatory amino acid, glutamate in excessive amounts in the synapse could trigger excitotoxicity and eventual neurodegeneration. 66 In fact, early models of HD relied on excessive activation of glutamate receptors to induce striatal degeneration. 29 More recent evidence points to a change in the clearance or removal of glutamate from the synapse after its release. 67 The expression of glutamate transporter-1 (GLT-1), the protein responsible for the removal of most extracellular glutamate in striatum and other forebrain regions, 68 is decreased in striatum of HD mouse models relative to WT. 69, 70 The decline in glutamate uptake is accompanied by an increase in extracellular glutamate. 71 Similarly, the GLT-1 equivalent in humans, excitatory amino acid transporter 2 (EAAT2), is also decreased in HD patients. 72, 73 Although an increase in glutamate transmission related to a decline of uptake is consistent with elevated striatal neuronal activity in the R6/2 model and increased neuronal excitability in HD patients, HD is not easily explained by glutamate excitotoxicity as the progression of HD precedes neuronal death. Moreover, treatments aimed at attenuating excitotoxicity have been largely ineffective. 74 A problem with glutamate removal, however, implies a problem with how striatal neurons process information, 75 a view consistent with the altered firing patterns identified in the striatum of multiple HD models.
| Ascorbate and the glutamate uptake problem
An interesting glutamate connection to HD is a problem with the regulation of ascorbate, an antioxidant vitamin whose release is closely tied to glutamate uptake. 30 31 At this point, the bulk of the evidence indicates that the ascorbate problem in HD is one of release, which links it directly to down-regulation of GLT-1.
| Up-regulation of glutamate transport
Treatment with ceftriaxone, a beta-lactam antibiotic that crosses the blood-brain barrier, increases striatal GLT-1 expression. 90 R6/2 mice, injected with ceftriaxone once daily for 5 days, were tested at 6 weeks of age when the behavioral phenotype was apparent but not strongly expressed. The mice not only show elevated GLT-1 expression in striatal tissue, but also an increase in striatal glutamate uptake, indicating a corresponding increase in function. 71 Ceftriaxone also improved the motor phenotype in multiple behavioral tests.
Importantly, the ceftriaxone-induced up-regulation of GLT-1, which does not involve a transcriptional mechanism, 91 continues to be effective at later ages when R6/2 mice are strongly symptomatic. 92 Thus, the mechanism for increasing GLT-1 expression remains functional despite a rapidly advancing neuropathology, although it may be too late to rescue a rapidly advancing behavioral phenotype.
The behavioral improvements associated with ceftriaxone treatment in the early symptomatic stage disappear within a week after the last administration, 71 which not only limits the therapeutic potential of ceftriaxone but also analysis of the underlying role of GLT- surgery. Systemic AAV9 has been shown to increase GLT-1 immunofluorescence in both cortex and striatum of HD mice, albeit with a higher transduction rate in cortex. 94 Transduction, moreover, occurs in astrocytes, the principal cell type that expresses the GLT-1 protein. 68 An assessment of individual astrocytes revealed that glutamate uptake activity depends on Kir4.1-type potassium channels, which provide the driving force for glutamate transport and which represent another potential therapeutic target for HD. 95 Preliminary studies are underway in which the Q175 mouse, a knock-in model of adult onset HD, 28 receives intravascular AAV9-EAAT2 before symptom onset and is then tested at regular intervals for subsequent changes in behavior and striatal electrophysiology. 96, 97 Early data suggest that AAV9-EAAT2 ameliorates selective aspects of motor decline. For example, motor coordination on the rotarod test and motor flexibility in the four-arm maze remain at WT levels for several months, while the performance of untreated or vehicle-treated Q175s deteriorates over time. 97 Moderate improvement in the quality of nests built from cotton nesting material, a measure of motor planning and sequencing, also occur following AAV9-EAAT2 treatment. 96 Other behaviors, however, such as locomotion and open-field activity, did not substantially deteriorate over time in the Q175 model, making it difficult to establish a complete phenotypic assessment of AAV9-EAAT2 in these mice.
At the neuronal level, viral treatment prevented the deterioration in striatal firing patterns, including the changes in spike bursting that appear in Q175s and other HD models. 96 Viral treatment also restored gamma oscillations in striatal LFP activity in conjunction with improved motor flexibility. 97 Thus, although further testing of AAV9-EAAT2 treatment is necessary, evidence to date suggests a reversal of striatal dysfunction in the Q175 model but more variable effects on behavior. It is not clear if these mixed results could be explained by a behavioral role for other circuits not affected by AAV9-EAAT2 or possible limitations of the Q175 behavioral phenotype.
Curiously, an assessment of the time course of change in extracellular glutamate after its synaptic release in striatal slices failed to reveal a decline in glutamate uptake in R6/2 mice compared to WT controls. 98 Most measures of uptake rely on the application of exogenous glutamate to striatal tissue, but under these conditions, uptake is dominated by axon terminals rather than astrocytes even though astrocytes play a much greater physiological role in F I G U R E 1 Schematic glutamate synapse showing potential therapeutic targets related to up-regulation of glutamate transport. The primary glutamate transporter (EAAT2/GLT-1), found mainly on astrocytes, clears glutamate (GLU) released from axon terminals. GLU uptake also triggers release of ascorbate (not shown) and activation of xCT, which takes up cystine and releases GLU. The GLU released by xCT targets pre-synaptic metabotropic GLU receptors (mGLUR) that dampen further GLU release from axon terminals. Under normal conditions, synaptic GLU acts on the NR2A subunit of the NMDA receptor to promote cell survival. In Huntington's disease (HD), with EAAT2/GLT-1, xCT, and NR2A down-regulated, synaptic GLU spills outside the synapse to bind the NR2B subunit, which is increased in HD and promotes cell death. Up-regulation of EAAT2/GLT-1 restores GLU homeostasis by increasing GLU uptake and reversing the HD-related changes in xCT, NR2A and NR2B glutamate clearance. 99 Thus, evidence for normal uptake of synap- 
| IMPLIC ATI ONS AND FUTURE PER S PEC TIVE S
Although frontocortical output neurons and the striatal output neurons they target are dysfunctional in the transgenic mice that model HD, further insight into the functional connectivity between cortex and striatum is necessary for developing an effective therapeutic strategy. The reason for this cautious assessment is that apart from understanding the integrated activity of individual neurons, neural circuits exhibit an additional layer of integration shaped by ongoing behavioral demands. Effective analysis of corticostriatal circuit operations, therefore, requires not only simultaneous recordings of cortical and striatal activity under multiple behavioral conditions but also sophisticated computational methods that can discern the dynamic changes in neural processing that shape behavior.
The complexity of the issue is reflected in how cortical and striatal neurons are believed to interact. A common view of corticostriatal connectivity is that cortex drives striatum in the control of behavioral output. By integrating sensorimotor and reward information, cortex is thought to mediate situational responding, while striatum consolidates learned routines into habits. 102, 103 But striatum, which also integrates sensorimotor and reward information, can be just as critical in shaping behavior. 104, 105 In fact, striatum responds more rapidly than cortex during associative learning, and striatal responses emerge first as learning occurs. 106 Thus, although the neural correlates of behavior have been observed in cortex and striatum, the underlying driver-receiver dynamics remain unclear. Equally important is evidence that corticostriatal communication can be bidirectional depending on behavioral state, 107 indicating that effective connectivity is neither unidirectional nor static.
These hard realities make an investigation of dysfunctional connectivity in HD difficult. 
| CON CLUS IONS
All HD mouse models tested to date under freely behaving conditions show abnormal neuronal spiking and LFP activity in cortex and striatum, suggesting a fundamental deficit in how corticostriatal neurons communicate. In fact, striatal dysfunction depends on the expression of mHTT in cortical output neurons, confirming the importance of cell interactions and their disruption by HD. The extracellular level of glutamate, released by corticostriatal afferents, is controlled by a high affinity uptake system that also triggers the release of ascorbate. Dysregulation of both glutamate uptake and ascorbate release, both of which influence neuronal excitability, is further evidence of corticostriatal dysfunction in HD. Increased expression of the glutamate transport protein normalizes glutamate transmission and improves both striatal electrophysiology and the HD behavioral phenotype. Identification of the mechanisms by which mHTT disrupts the interplay between glutamate and corticostriatal neuronal processing is a necessary step toward understanding and eventually treating the neuronal impairments underlying HD.
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